We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ResearchDx Completes Service Offerings by Partnering with CompanDX

By LabMedica International staff writers
Posted on 22 Jun 2011
ResearchDx (Irvine, CA, USA) is partnering with CompanDX (Nottingham, United Kingdom) to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting.

CompanDX uses its Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. More...
ResearchDx designs, produces and validates tests ready for the market and offers turnkey solutions for companion diagnostic delivery.

The new partnership will enable clients to initiate the development of companion diagnostic tests from the earliest stages of drug development. CompanDX has developed a set of tools to deliver an understanding of the mechanism of action and biomarkers that describe patient response.

ResearchDx is a Contract Diagnostics Organization (CDO) for the diagnostic and biopharmaceutic industries. The company's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. ResearchDx offers CLIA certified, CAP accredited high-complexity testing through its subsidiary, Pacific Diagnostics. It provides a full complement of cytogenetics, Fluorescence in situ hybridization (FISH), molecular and specialty services.

"Our partnership with CompanDX completes our service offerings," said founders of ResearchDx Dr. Philip Cotter and Dr. Mathew Moore. "CompanDX's unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process. Our customers can trust ResearchDx to meet scientific challenges with a focus on their business priorities."

Related Links:

ResearchDx
CompanDX



New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.